Dry Age-related Macular Degeneration
37
7
11
14
Key Insights
Highlights
Success Rate
74% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.5%
5 terminated out of 37 trials
73.7%
-12.8% vs benchmark
5%
2 trials in Phase 3/4
29%
4 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (37)
PRIMA US-Feasibility Study in Atrophic Dry AMD
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study